Microorganisms with reduced competence
By introducing point mutations into the bacteria's comK gene, reducing or eliminating its competent ability, the problem of bacteria obtaining unwanted antibiotic resistance genes from the environment is solved, ensuring its characteristic stability and safety, and maintaining probiotics activity.
Patent Information
- Application Number
- CN202380022213.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-17
- Filing Date
- 2023-02-03
- Publication Date
- 2024-12-06
AI Technical Summary
The ability of bacterial cells to obtain genetic information from the environment leads to their acquisition of unwanted antibiotic resistance genes, especially in probiotics that act as feed additives, affecting their characteristics and safety.
By introducing point mutations into the comK gene, knocking out or significantly reducing the competent mechanism of the bacteria, making it impossible to absorb DNA from surrounding media through natural transformation, specific methods include introducing a stop codon to reduce or eliminate the activity of the comK gene, and It may be combined with knockout or reduction of other competent genes.
The bacteria's competence is reduced, ensuring its characteristic stability and safety, avoiding undesired acquisition of antibiotic resistance genes, and has no negative impact on probiotic activity.
Smart Images

Figure BDA0004996243860000171
Abstract
Description
[0001] Subject matter of the present invention are microorganisms with reduced competence and compositions, in particular feed, food and pharmaceutical compositions, containing such microorganisms.
[0002] Many species of bacteria are able to bind and absorb DNA from the surrounding culture medium. This ability is called "competence" and enables bacterial strains to acquire new characteristics, especially adaptation to the environment. This process is also known as "natural transformation" (Breitling and Dubnau (1990); J Bacteriology 172 (3): 1499-1508). A problem associated with this ability is that strains may acquire unwanted antibiotic resistance genes, which is an undesirable feature of microbial strains released into the environment.
[0003] Therefore, the ability of bacterial cells to acquire genetic information from the environment is a problem for established production strains, especially for probiotics sold as feed additives, so their characteristics should not be altered either during production or later, when they are used in feed applications.
[0004] It is therefore an object of the present invention to provide microbial strains which, due to reduced competence, have a reduced ability to modify their genetic material by acquiring genetic information from the environment.
[0005] The object of the present invention can be solved by providing a microorganism having a knocked-out competent gene, wherein the knocked-out competent gene is preferably a transcription factor, more preferably the competent transcription factor comK.
[0006] Surprisingly, it was found that by introducing several point mutations in the comK gene, the competence mechanism of the microorganism could be knocked out, without the knockout of the comK gene having any adverse effect on the characteristics of the obtained cells, especially in terms of safety and risk, and had no negative impact on the probiotic activity.
[0007] Therefore, the first subject of the present invention is a microorganism with reduced competence, wherein "reduced competence" preferably means that the ability to absorb DNA from the surrounding medium by natural transformation is reduced by at least 50%, more preferably by at least 60%, 70% or 80%, and most preferably by at least 90% or 95% compared to the wild-type strain or parent strain. In a particularly preferred embodiment of the present invention, the microorganism of the present invention is not able to absorb DNA from the surrounding medium by natural transformation at all, i.e., the ability is reduced by 100%.
[0008] The reduction of cell competence is preferably determined by a stock solution containing 25 μg of plasmid DNA, more preferably as disclosed in working example 3.
[0009] The microorganism according to the invention preferably contains at least one competent gene which has been knocked out, or contains at least one competent gene which is accordingly expressed at a significantly reduced level and / or with a significantly reduced activity.
[0010] The at least one competent gene that is knocked out or whose expression or activity is significantly reduced is preferably a gene encoding a transcription factor, wherein very preferably, the competent gene is the competent transcription factor comK.
[0011] Preferably, the competent gene of the microorganism of the present invention, in particular the comK gene, comprises 1 to 20 mutations, more preferably 1 to 10 mutations, most preferably 1 to 5 mutations, compared to the wild type and / or parent strain from which the microorganism is derived, wherein the mutations are preferably point mutations. In a very preferred embodiment of the present invention, at least one of the mutations, preferably at least two of the mutations, leads to the introduction of a stop codon in the sequence encoding the competent gene, in particular comK, wherein very preferably, the comK parent sequence is the comK sequence according to SEQ ID NO: 1, as present in Bacillus velezensis strain CECT 5940, and wherein preferably at least one stop codon is introduced in positions 1 to 50 of the sequence encoding the competent gene, in particular the comK sequence. In a more preferred embodiment of the present invention, the microorganism contains at least one, preferably two of the following mutations in the comK gene, both of which lead to the introduction of a stop codon, respectively: substitution of adenine at position 10 by thymine; substitution of guanine at position 37 by thymine. In a particularly preferred embodiment of the present invention, the microorganism contains a comK mutant having the sequence of SEQ ID NO:2.
[0012] As an alternative and / or in addition to reducing and / or knocking out the activity of comK, the activity of at least one other and / or additional competent gene can be reduced and / or knocked out, in particular by introducing at least one stop codon into this gene. Such alternative and / or supplementary competent genes are in particular selected from the genes comGA, comGB, comGC, comGD, comGE, comGF, comGG, comS, comEA, comEC, comFA, dprA, ssbB and recA.
[0013] The microorganism of the present invention can be mainly obtained by any kind of method, i.e. by genetically modified organisms (GMO) or non-GMO methods. But preferably, the microorganism is not genetically modified, i.e. non-GMO. This means that the microorganism is preferably a naturally occurring microorganism, or a spontaneous mutant of this naturally occurring microorganism, or a microorganism obtained by another method classified as non-GMO. The term "spontaneous mutant" refers to a mutant produced by a naturally occurring microorganism and / or a parent strain, without genetically modifying the microorganism by applying classical gene technology and / or biotechnology methods (such as site-directed mutagenesis). This spontaneous mutant can be obtained by classical natural selection methods, for example, in the presence of ultraviolet rays and / or by applying high temperature or protoplast formation and / or cultivating microorganisms in the presence of certain antibiotics to which the parent strain is susceptible. Spontaneous mutants can be further, but less preferably, obtained by using a mutagen, i.e. a chemical substance that induces mutant formation. Since it is less preferred to form spontaneous mutants by using a mutagen, in a preferred embodiment of the present invention, spontaneous mutants and / or non-GMO mutants are obtained without using this mutagen. If the mutant is obtained by applying genetic and / or biotechnological methods such as site-directed mutagenesis, preferably a method classified as non-GMO is applied. The non-GMO method of the invention is preferably characterized in that the method does not involve the introduction of heterologous genetic information into the microorganism.
[0014] In a particularly preferred embodiment of the present invention, the microorganism of the present invention is a non-naturally occurring mutant, in particular a non-GMO and / or spontaneous mutant as defined above. The microorganism of the present invention preferably has the same characteristics as the parent strain from which they are derived, except for the reduced competence as described above. In a particularly preferred embodiment, the only difference in the genomic sequence between the microorganism of the present invention and the parent strain from which they are derived is the mutation in the comK sequence.
[0015] The microorganism of the present invention can be obtained, for example, by the following method:
[0016] a) introducing a reporter gene, preferably a reporter gene encoding a fluorescent marker, downstream of the promoter of the gene activated by the competent or regulatory gene, so that activation of the promoter leads to expression of the reporter gene;
[0017] b) screening conditions leading to competence induction by analyzing the microorganisms in terms of the expression level of the reporter gene;
[0018] c) introducing a knockout in a gene which results in auxotrophy of the strain and at the same time in resistance of the strain thus transformed to a specific substance;
[0019] d) searching for the knockout strain obtained in step (c) by screening strains with desired resistance;
[0020] e) co-transforming the strain identified in step (d) with an active form of the gene knocked out in step (c) and a knockout variant of a competent or regulatory gene,
[0021] f) searching for strains that exhibit prototrophy;
[0022] g) Screening the strain identified in step (f) to determine whether knockout of the regulatory gene is successful.
[0023] In the process, steps (c) and (e) and optionally step (g) are preferably carried out under the conditions determined in step (b) of the process.
[0024] The microorganism of the present invention is preferably obtained by the following method:
[0025] a) introducing a reporter gene, preferably a reporter gene encoding a fluorescent marker, downstream of the promoter of the competent gene comGA activated by comK, so that activation of the promoter leads to expression of the reporter gene,
[0026] b) screening conditions leading to induction of competence by analyzing the microorganisms with respect to the expression level of said reporter gene,
[0027] c) introducing a knockout in a gene which results in auxotrophy and at the same time in resistance to a specific substance, wherein the gene is preferably pyrE and the knockout preferably results in resistance to 5-fluoroorotic acid (5-FOA);
[0028] d) searching for knockout strains by screening strains with desired resistance, preferably resistance to 5-FOA;
[0029] e) co-transforming the strain identified in step (d) with an active form of the gene knocked out in step (c), ie preferably with an active form of pyrE and a knockout variant of comK;
[0030] f) finding strains that exhibit prototrophy;
[0031] g) screening the strain identified in step (f), preferably under the conditions identified in step (c), to determine whether the knockout of the regulatory gene comK is successful.
[0032] In this process, steps (c) and (e) and optionally also step (g) are preferably carried out under the conditions determined in step (b) of the process.
[0033] The microorganisms according to the invention are preferably further non-pathogenic, in particular non-pathogenic to humans and animals and preferably also non-pathogenic to plants.
[0034] The microorganisms of the present invention are preferably selected from the list of microorganisms generally recognized as safe ("GRAS") or listed as direct edible microorganisms ("DFM") or probiotics as described in the relevant list, such as but not limited to the EFSA QPS list, the AAFCO list or the list of the Ministry of Agriculture (MOA) of China.
[0035] The microorganism of the present invention is preferably sensitive to at least five antibiotics, more preferably to at least six, eight or ten antibiotics, and most preferably to at least 11 or 12 antibiotics, wherein the antibiotics are preferably selected from tylosin, nalidixic acid, trimethoprim, apramycin, sulfonamide, ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, chloramphenicol, nourseothricin, daptomycin and virginiamycin. In a very preferred embodiment, the microorganism of the present invention is sensitive to all of the aforementioned antibiotics.
[0036] "Sensitive to an antibiotic" means that the growth of the microorganism is inhibited by the antibiotic under conditions where the microorganism could otherwise grow. The sensitivity to the antibiotic is preferably tested according to the CLSI guidelines (M07-A8 and M45-A2). If growth is detected only at or below the breakpoint specified for vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol in EFSA Journal 2012; 10 (6): 2740, then the Bacillus strain is preferably considered to be sensitive. Regarding tylosin, nalidixic acid, trimethoprim, apramycin, sulfonamide, ampicillin, nourseothricin, daptomycin and virginiamycin, EFSA does not give its breakpoint for Bacillus, and the breakpoint is preferably 4 mg / L.
[0037] The microorganism of the present invention can be any kind of microorganism that is generally naturally competent, in particular bacteria that form endospores and / or bacteria that do not form spores, but in a preferred embodiment of the present invention, the microorganism is a bacteria that forms endospores. The cells of the endospore-forming bacteria of the present invention, in particular the cells in the composition of the present invention, can be present as spores (dormant), vegetative cells (growing), transitional cells (transitioning from the growth phase to the spore formation phase) or as a combination of at least two, in particular a combination of all these types of cells. In a preferred embodiment, the composition of the present invention mainly comprises or only comprises spores.
[0038] The microorganisms of the present invention are preferably selected from endospore-forming bacteria of the phylum Bacillota (formerly Firmicutes), preferably of the genus Bacillus, and more preferably selected from Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus velezensis, Bacillus licheniformis, Bacillus paralicheniformis, Bacillus pumilus, Bacillus megaterium, Bacillus lentus, Bacillus laterosporus, Bacillus alevi, Bacillus cereus, Bacillus badius, Bacillus thuringiensis ... Preferably, the present invention relates to Bacillus igiensis, B. coagulans, B. siamensis, B. glycinifermentans, B. methylotrophicus, B. thuringiensis, B. polyfermenticus, B. vallismortis, B. tequilensis, B. atrophaeus, B. mojavensis, B. sonorensis, B. inaquosus and B. safensis, and most preferably, they are species of B. velezii or B. amyloliquefaciens.
[0039] In a further preferred embodiment of the present invention, the microorganism of the phylum Bacillus is a species of the genus Clostridium, preferably C. butyricum, C. tyrobutyricum or C. acetobutylicum.
[0040] In a very preferred embodiment of the present invention, the microorganism of the present invention is a species of Bacillus Velez, more preferably, the genome sequence of the microorganism is at least 99%, in particular at least 99.5% or 99.8%, especially at least 99.9% or 99.99% identical to the genome sequence of Bacillus Velez strain CECT 5940. In a particularly preferred embodiment, the only difference in the genome sequence between strain CECT 5940 and the strain of the present invention is a mutation in the comK sequence.
[0041] In a very preferred embodiment of the present invention, the microorganisms according to the invention additionally have probiotic activity and / or can be used as directly edible microorganisms.
[0042] The microorganisms according to the invention particularly preferably have at least one, more preferably at least two, three, four or five further characteristics selected from the group consisting of:
[0043] a) Ability to grow rapidly in large bioreactors;
[0044] b) the ability to grow in the presence of bile, preferably in the presence of 2 mM or 4 mM bile and / or in the presence of 0.3 wt% bile;
[0045] c) the ability to grow in the presence of formic, acetic, propionic and / or lactic acid;
[0046] d) the ability to produce organic acids, especially lactic acid;
[0047] e) ability to grow under high salt conditions;
[0048] f) the ability to form endospores;
[0049] g) Ability to grow anaerobicly;
[0050] h) the ability to inhibit pathogenic bacteria, in particular Clostridium perfringens, Salmonella enteritidis, Salmonella typhimurium, Escherichia coli, Clostridium difficile and / or Vibrio parahaemolyticus;
[0051] i) the ability to produce at least one enzyme, preferably selected from the group consisting of amylase, lipase, catalase, cellulase, xylanase and protease;
[0052] j) susceptibility to selected antibiotics;
[0053] k) the ability to produce biosurfactants, in particular surfactant peptides (surfactins);
[0054] l) The ability to modulate the microbiome.
[0055] The microorganisms of the present invention, in particular microorganisms of the genus Bacillus, are preferably capable of rapid growth in large-scale bioreactors. Specifically, this means that the doubling rate of heterotrophic growth in a stirred tank reactor in the absence of light is less than 60 minutes.
[0056] The microorganisms according to the invention are further preferably characterized in that they are able to grow in the presence of 2 mM bile, preferably in the presence of 4 mM bile, in particular characterized in that in the presence of 2 mM bile, the AUC5 performance value is at least 0.5, preferably at least 0.65, in particular at least 0.8, and the AUC10 performance value is at least 1.2, preferably at least 1.4, in particular at least 1.6, and / or they are able to grow in the presence of 0.3 wt. % bile, in particular in the presence of 0.3 wt. % chicken bile and / or 0.3 wt. % porcine bile, preferably characterized in that they are able to survive exposure to 0.3 wt. % bile, in particular to 0.3 wt. % chicken bile and / or 0.3 wt. % porcine bile for at least 3 hours, preferably at least 5 or 8 hours.
[0057] The microorganisms of the present invention are preferably further characterized by being capable of anaerobically growing, in particular being capable of degrading water-insoluble cellulose and / or proteins under anaerobic conditions.
[0058] The microorganism of the invention is preferably further characterized in that at least 50%, preferably at least 70% or 90% of the spores survive after exposure to 99°C for 20 minutes.
[0059] The microorganism of the present invention is preferably used to prepare a feed additive composition or a food additive composition by mixing the microorganism with a suitable carrier.
[0060] In a particularly preferred embodiment of the present invention, the microorganisms according to the invention are used in the form of a preferably dry fermentation broth, wherein "dry" preferably means a residual water content of 0.1% to 10% by weight, more preferably 0.2% to 5% by weight, most preferably 0.3% to 4% by weight.
[0061] Therefore, another theme of the present invention is also the feed additive or food additive containing the microorganism of the present invention, wherein the microorganism particularly can be provided in the form of the dry fermentation liquid of this microorganism.The feed additive or food additive of the present invention preferably comprise 0.1 % by weight to 10 % by weight, more preferably 0.2 % by weight to 5 % by weight, particularly the microorganism or its dry fermentation liquid of the amount of 0.3 % by weight to 3 % by weight.The feed additive or food additive preferably further comprise a carrier, particularly at least 80 % by weight, preferably at least 90 % by weight or at least 95 % by weight, particularly the carrier of the amount of 90 % by weight to 99.9 % by weight or 95 % by weight to 99.8 % by weight or 97 % by weight to 99.7 % by weight.In a preferred embodiment of the present invention, the feed additive or food additive is only composed of the mixture of the dry fermentation liquid of microorganism or this microorganism and the carrier.
[0062] The feed additive or food additive preferably contains microorganisms in an amount of 1 x 10 9 cfu to 1x 10 11 cfu (colony forming units), more preferably containing 5 x 10 microorganisms per gram of feed additive or food additive. 9 cfu to 5x 10 10 cfu.
[0063] The carrier contained in the feed additive or food additive is preferably selected from inert formulation ingredients, which are added to improve recovery, efficacy or physical properties and / or to help packaging and administration. These carriers can be added individually or in combination. These carriers can be selected from anti-caking agents, antioxidants, fillers, adhesives, structurants, coatings and / or protective agents. Examples of useful carriers include polysaccharides (especially starch, maltodextrin, methylcellulose, gums, chitosan and / or inulin), protein sources (especially skimmed milk powder and / or sweet whey powder), protein hydrolysates (especially peptones, such as soy peptone and / or yeast extract), peptides, sugars (especially lactose, trehalose, sucrose and / or dextrose), lipids (especially lecithin, vegetable oils and / or mineral oils), salts (especially sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and / or sodium citrate) and silicates (especially clays, especially beolite clay, amorphous silica, fumed / precipitated silica, zeolites, Fuller's earth, The carrier can be added after the fermentation broth containing the microorganism of the present invention is concentrated and / or during and / or after the fermentation broth is dried.
[0064] The feed additives or food additives according to the invention preferably have a residual moisture content of 0.1% to 6% by weight, preferably 0.3% to 5% by weight, more preferably 0.5% to 4% by weight. They further preferably exhibit a water activity (a) of 0.05 to 0.6, preferably 0.1 to 0.5. w value).
[0065] Another subject of the present invention is also a method for preparing the feed additive or food additive according to the invention, wherein the microorganism according to the invention or the dried fermentation broth of this microorganism is mixed with a carrier, in particular with a carrier as described above, preferably adjusted to 1×10 9 cfu to 1×10 11 The amount of cfu (colony forming units) is preferably adjusted to 5×10 per gram of feed additive or food additive. 9 cfu to 5×10 10 cfu amount mixed.
[0066] Feed additives as previously mentioned, such as microorganisms themselves, can be used for preparing feeds and pharmaceutical compositions, and can be added to drinking water and feeding water. In a preferred embodiment, 0.1kg to 100kg of feed additives, particularly 1kg to 10kg of feed additives are used in per ton of feed, drinking water or feeding water to provide a composition that can be used for feeding animals. Feed and food compositions can be prepared by mixing the feed additives or food additives with typical feed ingredients or food ingredients, respectively.
[0067] Therefore, another subject of the present invention is also a feed or food composition which contains the microorganisms and / or the feed or food additive according to the invention and preferably at least one further feed or food ingredient.
[0068] Therefore, a further subject of the present invention is also the use of the microorganisms according to the invention and / or the feed additive or food additive according to the invention for preparing a feed composition or food composition.
[0069] Therefore, a further subject of the present invention is also a process for preparing a feed or food composition according to the invention, wherein the microorganisms according to the invention and / or the food or feed additive according to the invention are mixed with further feed or food additives.
[0070] Another subject of the present invention is also a pharmaceutical composition containing the microorganism according to the invention and at least one pharmaceutically acceptable carrier.
[0071] Therefore, another subject of the present invention is also the use of the microorganisms according to the invention and / or the feed additives or food additives according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment, prevention or alleviation of intestinal disease processes.
[0072] Therefore, another subject of the present invention is also a process for the preparation of the pharmaceutical composition according to the invention, wherein the microorganism according to the invention and / or the feed additive or food additive according to the invention are mixed with a pharmaceutically acceptable carrier.
[0073] Endospore-forming bacteria of the genus Bacillus, in particular of the species Bacillus Velez, especially of the strain Bacillus Velez CECT 5940, are generally known to have beneficial effects on the intestinal tract of animals and humans.
[0074] Thus, when administered to an animal, the microorganisms of the present invention preferably enhance the health of such animals and / or improve the general physical condition of such animals and / or improve the feed conversion rate of such animals and / or reduce the mortality of such animals and / or increase the survival rate of such animals and / or improve the weight gain of such animals and / or increase the productivity of such animals and / or enhance the disease resistance of such animals and / or modulate the immune response of such animals and / or establish or maintain a healthy intestinal microbiota in such animals and / or improve the meat quality of such animals, in particular the elasticity of the meat and / or the firmness of the meat, and / or reduce the transmission of bacterial and / or viral pathogens through the feces of such animals. In particular, the microorganisms and compositions of the present invention can be used to help reestablish a healthy balance of intestinal microbiota after the administration of antibiotics for therapeutic purposes.
[0075] Therefore, another subject of the present invention is a method for enhancing the health of an animal and / or improving the general physical condition of an animal and / or improving the feed conversion rate of an animal and / or reducing the mortality rate of an animal and / or increasing the survival rate of an animal and / or improving the weight gain of an animal and / or increasing the productivity of an animal and / or enhancing the disease resistance of an animal and / or modulating the immune response of an animal and / or establishing or maintaining a healthy intestinal microbiota in an animal and / or improving the meat quality of an animal and / or reducing the transmission of bacterial and / or viral pathogens through the feces of an animal, wherein at least one microorganism and / or at least one feed additive and / or at least one composition according to the invention is administered to the animal.
[0076] Therefore, another subject of the present invention is also a method for enhancing the health of a human and / or improving the general physical condition of a human and / or enhancing disease resistance in a human and / or modulating the immune response in a human and / or establishing or maintaining a healthy intestinal microbiota in a human, wherein at least one microorganism and / or at least one composition according to the invention is administered to the human.
[0077] Therefore, another subject of the present invention is also the use of at least one microorganism and / or at least one feed additive and / or at least one composition according to the invention for (in the preparation of a composition for) enhancing the health of an animal and / or improving the general physical condition of an animal and / or improving the feed conversion rate of an animal and / or reducing the mortality rate of an animal and / or increasing the survival rate of an animal and / or improving the weight gain of an animal and / or increasing the productivity of an animal and / or enhancing the disease resistance of an animal and / or modulating the immune response of an animal and / or establishing or maintaining a healthy intestinal microbiota in an animal and / or improving the meat quality of an animal and / or reducing the transmission of bacterial and / or viral pathogens through the feces of an animal, wherein at least one microorganism and / or at least one feed additive and / or at least one composition according to the invention is administered to the animal.
[0078] Therefore, another subject of the present invention is also the use of at least one microorganism and / or at least one composition according to the invention for (in the preparation of a composition for) enhancing the health of a human and / or improving the general physical condition of a human and / or enhancing disease resistance in a human and / or modulating an immune response in a human and / or establishing or maintaining a healthy intestinal microbiota in a human, wherein the at least one microorganism and / or at least one composition according to the invention is administered to the human.
[0079] Therefore, another subject of the present invention is also at least one microorganism and / or at least one feed additive or food additive and / or at least one composition according to the invention for enhancing the health of animals and / or humans and / or for improving the general physical condition of animals and / or humans and / or for improving the feed conversion rate of animals and / or reducing the mortality rate of animals and / or increasing the survival rate of animals and / or for improving the weight gain of animals and / or increasing the productivity of animals and / or enhancing disease resistance in animals and / or humans and / or modulating the immune response of animals and / or humans and / or establishing or maintaining a healthy intestinal microbiota of animals and / or humans and / or for improving the meat quality of animals and / or reducing the transmission of bacterial and / or viral pathogens through the feces of animals.
[0080] “Increasing the productivity of an animal” means in particular any of the following: producing more or better quality eggs, milk or meat, or increasing the number of offspring or improving the survival of offspring.
[0081] By using the microorganisms, feed additives or food additives and compositions of the present invention, it is preferred to achieve an improvement in at least one of the aforementioned characteristics, wherein the achievement of said characteristics preferably means an improvement of at least 1%, more preferably at least 3% or at least 5% compared to an adequate negative control. Mean values known in the field of animal husbandry can be used as negative controls, but control animals that receive the same treatment as the test animals but do not administer the microbial preparations and / or compositions of the present invention are preferably used as negative controls.
[0082] In particular, the microorganism, preparation and composition of the present invention can be used or fed to animals with the amount of effectively inhibiting and / or reducing the growth of pathogenic bacteria in the animal intestinal tract. The pathogenic bacteria include clostridium, salmonella, vibrio and Escherichia coli, and in addition, especially also include Listeria, enterococci, staphylococci, aeromonas, streptococci, campylobacter, shigella, haemophilus and brachyspira. Relatedly, the method of the present invention can be used to reduce the amount of pathogenic bacteria, viruses and protozoa scattered in animal feces. The method of the present invention can also be used to maintain or increase the growth of beneficial bacteria such as lactic acid bacteria in the animal intestinal tract. By reducing pathogenic bacteria and / or increasing or maintaining beneficial bacteria, the composition of the present invention can maintain the intestinal microbial population of overall health.
[0083] Therefore, another subject of the present invention is also a method for inhibiting and / or reducing the growth of pathogenic bacteria, and / or maintaining and / or increasing the growth of beneficial bacteria, in particular in the intestinal tract of animals or humans, wherein the microorganisms, preparations and / or compositions according to the invention are administered to the animal or human, wherein the pathogenic bacteria are preferably selected from: Clostridium, in particular Clostridium perfringens, Clostridium difficile, Clostridium novyi, Clostridium septicum and Clostridium colinum; Listeria, in particular Listeria monocytogenes (L.monocytogenes), Listeria seeligeri and Listeria welshimeri (L.welshimeri); Salmonella, especially Salmonella enterica (S.enterica) (including Salmonella enterica subspecies, Salmonella arizonae, Salmonella bongori and especially Salmonella enterica serovar), Salmonella gallinarum, Salmonella pullorum, Salmonella typhimurium (S. .typhimurium), S.enteritidis, S.cholerasuis, S.heidelberg, S.dublin, S.hadar, S.typhi, S.paratyphi, and S.infantis; Enterococci, especially E.faecalis, E.faecium, ecium and E. cecorum; Staphylococci, in particular S. aureus; Aeromonas; Streptococci, in particular S. suis and S. gallinaceus; Campylobacter, in particular C. jejuni and C. coli; Escherichia coli; Haemophilus, in particular Haemophilus parasuis; Brachyspira, in particular Brachyspira hyodysenteriae; and Vibrio, in particular V. parahaemolyticus and V. harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, in particular Lactobacillus and Bifidobacterium.In a preferred embodiment, the pathogenic microorganism is selected from Clostridium, in particular Clostridium perfringens, Salmonella, in particular Salmonella enterica and Vibrio, in particular Vibrio parahaemolyticus.
[0084] In a preferred embodiment of the invention the amount of at least one pathogenic bacterium, in particular Clostridium perfringens, Salmonella enterica and / or Vibrio parahaemolyticus is reduced by at least 0.5 log, more preferably at least 1 log, 2 log or 3 log.
[0085] Therefore, another subject of the present invention is also the microorganisms, preparations and compositions according to the invention for inhibiting and / or reducing the growth of pathogenic bacteria, and / or maintaining and / or increasing the growth of beneficial bacteria, in particular in the intestinal tract of animals or humans, wherein the pathogenic bacteria are preferably selected from Clostridium, in particular Clostridium perfringens, Clostridium difficile, Clostridium novyi, Clostridium septicum and Clostridium intestinale; Listeria, in particular Listeria monocytogenes, Listeria monocytogenes and Listeria welshimeri; Salmonella, in particular Salmonella enterica (including Salmonella enterica subspecies, Salmonella arizona, Salmonella bongori and in particular Salmonella enterica serovars), Salmonella Gallinarum, Salmonella Pullorum, Salmonella enterica, Salmonella enteritidis, Salmonella choleraesuis, Salmonella Heidelberg, Salmonella Dublin, Salmonella Hadar, Salmonella typhi, Salmonella paratyphi and Salmonella infantis; Enterococci, especially Enterococcus faecalis, Enterococcus faecium and Enterococcus cecum; Staphylococci, especially Staphylococcus aureus; Aeromonas; Streptococci, especially Streptococcus suis and Streptococcus gallinarum; Campylobacter, especially Campylobacter jejuni and Campylobacter coli; Escherichia coli; Haemophilus, especially Haemophilus parasuis; Brachyspira, especially Brachyspira hyodysenteriae; and Vibrio, especially Vibrio parahaemolyticus and Vibrio harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, especially Lactobacillus and Bifidobacterium. In a preferred embodiment, the pathogenic microorganism is selected from Clostridium, in particular Clostridium difficile and Clostridium perfringens; Salmonella, in particular Salmonella typhimurium and Salmonella enteritidis; Vibrio, in particular Vibrio parahaemolyticus and Escherichia coli.
[0086] The presence and / or increased growth of pathogenic bacteria does or may lead to outbreaks of certain diseases. For example, the presence and / or increased growth of Clostridium perfringens can lead to outbreaks of enteric disease, particularly necrotic enteritis in pigs and poultry. The presence and / or increased growth of Clostridium perfringens can also lead to outbreaks of other diseases such as bacterial enteritis, gangrenous dermatitis and cholangiohepatitis. Even the mildest forms of infection with Clostridium perfringens may be accompanied by diarrhoea, leading to wet litter, which may lead to secondary diseases such as footpad dermatitis. Although type C of Clostridium perfringens is generally considered to be the main cause of necrotic enteritis and necrotizing hemorrhagic enteritis in piglets, type A has been associated with intestinal disease in suckling and fed pigs with mild necrotizing enterocolitis and villous atrophy.
[0087] Clostridium difficile is an important emerging pathogen that primarily causes diarrhea in neonatal pigs. Infected piglets may experience respiratory distress, abdominal distension, and scrotal edema.
[0088] Staphylococcus aureus subsp. aureus can cause poultry foot inflammation in chickens, streptococcal mastitis in sows, and can produce toxins that cause food poisoning in humans.
[0089] Salmonella is an important cause of food poisoning in humans, often associated with the consumption of meat, such as poultry, pork or their derived products. Therefore, the control of Salmonella is a major challenge for the meat production industry. In Europe, a baseline study on the prevalence of salmonella in laying hen flocks in 2005 showed that 20.3% of large-scale laying hen farms throughout the EU were positive for Salmonella enteritidis. In some countries, the prevalence of Salmonella is even higher than 80% [European Food Safety Authority (2006), "Preliminary report: analysis of the baseline study on the prevalence of salmonella in laying hen flocks of Gallus gallus"].
[0090] V. parahaemolyticus in particular causes diseases in crustaceans, such as early mortality syndrome (EMS), also known as acute hepatopancreatic necrosis disease (AHPND), which affects giant tiger prawns (Penaeus monodon) and whiteleg shrimp (Penaeus vannamei).
[0091] The pathogen can cause other diseases such as polyarthritis, fibrinous polyserositis, post-weaning enteric diseases such as post-weaning diarrhoea, and edema disease, as well as swine dysentery.
[0092] Therefore, a preferred subject matter of the present invention is a therapeutic composition for the treatment of diseases, in particular for the treatment of intestinal diseases, in particular intestinal diseases associated with bacterial infections caused by Clostridium, in particular Clostridium difficile or Clostridium perfringens and / or Salmonella, in particular Salmonella enterica, preferably S. enterica subsp. enterica enteritidis or Salmonella typhimurium and / or Vibrio, in particular Vibrio parahaemolyticus and / or Escherichia coli.
[0093] Therefore, a further preferred subject matter in this context is a therapeutic composition for the treatment and / or prevention of necrotic enteritis and / or necrotic hemorrhagic enteritis, in particular subclinical necrotic enteritis and / or necrotic hemorrhagic enteritis, in animals (preferably pigs or poultry), said therapeutic composition comprising the strain and / or preparation and / or composition of the present invention.
[0094] Therefore, a further preferred subject matter in this context is a therapeutic composition for the treatment and / or prevention of early mortality syndrome in animals, preferably aquaculture animals, more preferably crustaceans, in particular shrimps and prawns, which therapeutic composition comprises the microorganisms and / or preparations and / or compositions according to the invention.
[0095] Therefore, a further preferred subject matter in this context is a therapeutic composition for the treatment and / or prevention of diseases caused by food poisoning, which comprises the microorganisms and / or preparations and / or compositions according to the invention.
[0096] Therefore, another preferred subject matter in this context is a therapeutic composition for the treatment and / or prevention of bacterial enteritis, gangrenous dermatitis, cholangiohepatitis, clostridial disease, diarrhea, dyspnea, abdominal distension, scrotal edema, poultry foot inflammation, foot pad dermatitis, streptococcal mastitis, lameness, arthritis, polyarthritis, fibrinous polyserositis, post-weaning intestinal disorders (e.g. post-weaning diarrhea) and edema disease, dysentery, osteomyelitis, inflammation of joints and / or bone tissue, pericardial inflammation, splenomegaly, hepatomegaly, nephromegaly, congestion, necrosis, liver or spleen infarction, valvular endocarditis, septicemia and / or meningitis in animals, preferably pigs or poultry, which therapeutic composition comprises a microorganism and / or a preparation and / or a composition according to the invention.
[0097] Therefore, another subject of the present invention is also the treatment and / or prevention of diseases associated with bacterial infections with Clostridia, in particular Clostridium perfringens and / or Salmonella, in particular Salmonella enterica, preferably Salmonella enterica subspecies Enteritidis and / or Vibrio, in particular Vibrio parahaemolyticus, in particular intestinal diseases, wherein the microorganisms and / or preparations and / or compositions according to the invention are administered to an animal in need thereof, wherein the animal is preferably a pig or poultry.
[0098] Therefore, another subject matter of the present invention is also the treatment and / or prevention of diseases, in particular intestinal diseases, preferably necrotic enterocolitis or necrotic hemorrhagic enterocolitis, in particular subclinical necrotic enterocolitis or subclinical necrotic hemorrhagic enterocolitis, wherein the microorganisms and / or preparations and / or compositions according to the invention are administered to an animal in need thereof, wherein the animal is preferably a pig or poultry.
[0099] Therefore, another subject of the present invention is also the treatment and / or prevention of diseases, in particular early mortality syndrome, in aquatic animals, wherein the microorganisms and / or preparations and / or compositions according to the invention are administered to an animal in need thereof, wherein the animal is preferably an aquaculture animal, more preferably a crustacean, in particular shrimps and prawns.
[0100] Therefore, another subject matter of the present invention is also the treatment and / or prevention of diseases caused by food poisoning, wherein the microorganisms and / or preparations and / or compositions according to the invention are administered to an animal or human in need thereof.
[0101] Therefore, another subject matter of the present invention is also the treatment and / or prevention of diseases caused by food poisoning, wherein the microorganisms and / or preparations and / or compositions according to the invention are applied to animal products, in particular meat or eggs, in order to avoid poisoning in humans.
[0102] Therefore, another subject of the present invention is also the treatment and / or prevention of diseases, preferably diseases of pigs or poultry, selected from bacterial enteritis, gangrenous dermatitis, cholangiohepatitis, clostridial disease, diarrhea, dyspnea, abdominal distension, scrotal edema, poultry foot inflammation, foot pad dermatitis, streptococcal mastitis, lameness, arthritis, polyarthritis, fibrinous polyserositis, post-weaning intestinal disorders (e.g. post-weaning diarrhea) and edema disease, dysentery, osteomyelitis, inflammation of joints and / or bone tissue, pericardial inflammation, splenomegaly, hepatomegaly, nephromegaly, congestion, necrosis, liver or spleen infarction, valvular endocarditis, septicemia and / or meningitis, wherein the microorganisms and / or preparations and / or compositions according to the invention are administered to an animal in need thereof.
[0103] The method and use of the microorganism, feed additive or food additive and composition of the present invention can be pharmaceutical or non-pharmaceutical, particularly therapeutic or non-therapeutic. In a particularly preferred embodiment of the present invention, the method and use are non-pharmaceutical, particularly non-therapeutic, preferably feed and food applications.
[0104] Preferred food compositions of the invention are fermented foods and / or dairy products, in particular yoghurt, cheese, milk, butter, curd and natto. The microorganisms of the invention can be used in particular in beverages and milk substitutes, such as infant formula.
[0105] The pharmaceutical compositions of the present invention preferably contain at least one pharmaceutically acceptable carrier. They may also contain other ingredients, such as typical food ingredients as further listed below.
[0106] The pharmaceutical composition of the present invention is preferably a liquid, paste, aerosol, tablet, suppository or dry composition, especially for application to the pharynx / respiratory tract, gastrointestinal tract, urogenital tract or skin. Administration can be carried out using a medical device, such as a nebulizer, pump or inhaler.
[0107] Therefore, another subject of the present invention is also a process for the preparation of a pharmaceutical composition, wherein the microorganism according to the invention is mixed with a pharmaceutically acceptable carrier and optionally further compounds, and wherein the pharmaceutical composition can be provided in the form of a medical device.
[0108] Another subject of the present invention is also, in particular, a nutritional supplement containing the microorganisms according to the invention and at least one pharmaceutically acceptable carrier.
[0109] In a preferred embodiment of the invention, the microorganisms and compositions of the invention are orally administered to animals or humans. Administration is preferably carried out in the form of feed and food compositions, but can also be carried out by applying the microbial preparations of the invention or feed additives to drinking water or feeding water. Therefore, another subject of the present invention is water, in particular an aqueous solution or an aqueous suspension containing at least one microorganism of the invention or feed additive.
[0110] Specifically, when the microorganisms and compositions of the present invention are applied to drinking water or breeding water, they can be applied in the form of a composition, particularly a tablet, which is easily dissolved after exposure to drinking water or breeding water and releases the microorganisms into the water environment. Such compositions, particularly tablets, are another preferred embodiment of the present invention. These compositions preferably include a carrier, such as a betaine salt, a citrate, a carbonate and / or a bicarbonate, such as disclosed in WO 2020 / 225020.
[0111] The feed, food and pharmaceutical composition of the present invention, as well as drinking water, feeding water, sewage or wastewater preferably contains about 1×10 2 CFU is about 1x10 10 The ratio of CFU of microorganisms is preferably about 1x10 per gram of feed or per milliliter of water. 4 CFU is about 1x10 9 The amount of CFU of microorganisms is preferably about 1x10 per gram of feed or per milliliter of water. 6 CFU to 1x10 8 CFU is the amount of microorganisms.
[0112] Accordingly, the preferred amount of the feed additive or food additive of the present invention in the feed, food and water composition of the present invention ranges from 0.01 wt% to 10 wt%, more preferably from 0.05 wt% to 5 wt%, especially from 0.1 wt% to 2 wt%.
[0113] The feed, food and pharmaceutical compositions of the present invention may contain additional carriers or other typical feed ingredients or combinations thereof.
[0114] Suitable carriers for the preparation of feed, food and pharmaceutical compositions are the same as those mentioned above for the preparation of feed additives or food additives starting from the microorganisms of the invention or fermentation broths of such microorganisms.
[0115] Suitable typical animal feed ingredients that may be included in the composition of the invention and / or used for preparing a feed composition or a food composition starting from the microorganisms and / or microbial fermentation broths and / or feed additives or food additives of the invention include one or more of the following: proteins, carbohydrates, fats, other probiotics, prebiotics, enzymes, vitamins, immunomodulators, milk replacers, minerals, amino acids, carriers, coccidiostats, acid-based products and / or drugs, such as antibiotics.
[0116] Carbohydrate-containing components which can be used according to the invention are, for example, forage, roughage, wheat meal, corn meal, sunflower meal or soybean meal, and mixtures thereof.
[0117] Protein-containing ingredients that can be used in the present invention are, for example, soy protein, pea protein, wheat gluten, corn gluten, rice, canola meal, marine animal meal (especially fish meal), terrestrial animal meal and mixtures thereof. "Marine animal meal" includes meat meal, meat and bone meal, blood meal, liver meal, poultry meal, silkworm meal, silkworm pupa meal and combinations thereof.
[0118] Fat is usually provided in the form of marine animal oil, vegetable oil or microbial oil (particularly microalgae oil) or its combination. The example of vegetable oil has soybean oil, rapeseed oil, sunflower seed oil, canola rapeseed oil (canola oil), cottonseed oil, linseed oil and palm oil. Marine animal oil includes fish oil and oil of krill, bivalves, squid or shrimp, and other fatty oils from fish of Engraulidae, Carangidae, Clupeidae, Osmeridae, Scombridae and / or Ammodytidae. The example of microalgae oil is particularly the oil of Labyrinthulea, preferably the oil of Schizochytrium (Schizochytria) or Thraustochytria (Thraustochytria). In addition to the separated oil, defatted biomass itself can also be used as fat source, ie in particular marine animal meal, preferably fish meal, or vegetable meal, in particular soya meal, rapeseed meal, sunflower meal, canola meal, cottonseed meal and / or linseed meal.
[0119] Protein-containing components which additionally contain fat and which can be used according to the invention are, for example, fish meal, krill meal, bivalve meal, squid meal or shrimp shells, and combinations thereof.
[0120] The feed according to the invention preferably has a total protein content of 20% to 50% by weight and / or a total fat content of 1% to 15% by weight and / or a total carbohydrate content of 20% to 60% by weight.
[0121] The other probiotics (DFM) and / or microorganisms which can be used according to the invention in combination with the microorganisms and feed additives or food additives of the invention are preferably bacteria selected from the group consisting of Bacillus subtilis, Bacillus licheniformis, Bacillus paralicheniformis, Bacillus lentus, Bacillus brevis, Bacillus laterosporus, Bacillus coagulans, Bacillus alevi, Bacillus cereus, Bacillus chestnut brown, Bacillus thuringiensis, Bacillus amyloliquefaciens, Bacillus Velez, Enterococcus faecium and Pediococcus acidilactici. Preferred examples are Bacillus pumilus DSM 32539 and Bacillus subtilis DSM 32540 (both deposited with the DSMZ on June 14, 2017 under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure) and their derivatives; Bacillus licheniformis DSM 32314 and Bacillus subtilis DSM 32315 (both deposited with the DSMZ on May 12, 2016 under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure) and their derivatives; Bacillus subtilis PB6 (as described in U.S. Patent No. 7,247,299 and deposited under ATCC Accession No. PTA-6737), which is registered by Kemin under the trademark Bacillus subtilis C-3102 (described in U.S. Pat. No. 4,919,936 and deposited as FERM BP-1096 at the Institute of Fermentation, Industrial Science and Technology, Japan), which was purchased by Calpis Sold; Bacillus subtilis DSM 17299, which is marketed by Chr. Hansen under the trademark Sold; Bacillus licheniformis DSM 17236, which is marketed by Chr. Hansen under the trademark Sold as a mixture of spores of Bacillus licheniformis DSMZ 5749 and Bacillus subtilis DSMZ 5750, marketed by Chr. Hansen under the trademark Bacillus subtilis DSM 29784, sold by Adisseo / Novozymes under the trademark Sold; Bacillus subtilis, marketed by Chr. Hansen under the trademark Sold; Bacillus licheniformis DSM 28710, by Hevepharma as Sold under the trademark; three strains of Bacillus probiotics, sold by DuPont under the trademark PRO for sale; Probiotics PureGro TM, sold by DSM; or Bacillus coagulans microorganisms, as described in U.S. Patent No. 6,849,256. Other non-bacillus probiotics, such as Saccharomyces cerevisiae, Pichia pastoris, Aspergillus niger, Aspergillus oryzae or Hansen yeast, can also be used in the composition of the present invention. In particular, in food compositions, other probiotics known to be useful for human health can be used, such as lactic acid bacteria of the order Lactobacillus, more preferably lactic acid bacteria of the order Aerococcaceae, Carnobacteriaceae, Enterococcus, Lactobacillaceae, Leuconotocaceae or Streptococcus, or lactic acid bacteria of the order Bifidobacterium, preferably Bifidobacterium, in particular lactic acid bacteria of the genus Bifidobacterium. If the other probiotics are not formulated as part of the composition of the present invention, they can be applied together with the composition of the present invention (at the same time or at different times).
[0122] Prebiotics that can be used according to the present invention are preferably oligosaccharides, in particular selected from galacto-oligosaccharides, sialic acid oligosaccharides, lactulose, lactosucrose, fructo-oligosaccharides, palatinose or isomaltooligosaccharides, glucosylsucrose, maltooligosaccharides, isomaltooligosaccharides, cyclodextrins, gentio-oligosaccharides, soy-oligosaccharides, xylo-oligosaccharides, dextran, pectin, polygalacturonic acid, rhamnogalacturonic acid, mannan, hemicellulose, arabinogalactan, arabinan, arabinoxylan, resistant starch, melibiose, chitosan, agarose, inulin, tagatose, polydextrose and alginate.
[0123] The enzymes that can be used in the feed composition of the present invention and that can contribute to the digestion of the feed are preferably selected from the group consisting of phytases (EC 3.1.3.8 or 3.1.3.26), xylanases (EC 3.2.1.8), galactanases (EC 3.2.1.89), galactosidases, in particular α-galactosidases (EC 3.2.1.22), proteases (EC 3.4), phospholipases, in particular phospholipases A1 (EC 3.1.1.32), A2 (EC 3.1.1.4), C (EC 3.1.4.3) and D (EC 3.1.4.4), lysophospholipases (EC 3.1.1.5), amylases, in particular α-amylases (EC 3.2.1.1), lysozymes (EC 3.2.1.17), glucanases, in particular β-glucanases (EC 3.2.1.4 or EC 3.2.1.23), lysozymes (EC 3.2.1.24), lysozymes (EC 3.2.1.25), lysozymes (EC 3.2.1.26), lysozymes (EC 3.2.1.27), lysozymes (EC 3.2.1.28), lysozymes (EC 3.2.1.29), lysozymes (EC 3.2.1.30), lysozymes (EC 3.2.1.31), lysozymes (EC 3.2.1.32), lysozymes (EC 3.2.1.33), lysozymes (EC 3.2.1.34), lysozymes (EC 3.2.1.35), lysozymes (EC 3.2.1 3.2.1.6), glucoamylase, cellulase, pectinase, or any mixture thereof.
[0124] Examples of commercially available phytases include Bio-FeedTM Phytase (Novozymes), P and HiPhos TM (DSM Nutritional Products), Natuphos TM (BASF), and Blue(AB Enzymes), XP (Verenium / DuPont) and PHY (DuPont). Other preferred phytases include, for example, those described in WO 98 / 28408, WO 00 / 43503 and WO 03 / 066847.
[0125] Examples of commercially available xylanases include WX and G2 (DSM NutritionalProducts), XT and Barley (AB Vista), (Verenium) and XB (xylanase / β-glucanase, DuPont). Examples of commercially available proteases include ProAct (DSM Nutritional Products).
[0126] Vitamins that can be used in the present invention are, for example, vitamin A, vitamin D3, vitamin E, vitamin K (e.g., vitamin K3), vitamin B12, biotin, choline, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, and pantothenate (e.g., calcium D-pantothenate) or a combination thereof.
[0127] Immunomodulators that may be used are, for example, antibodies, cytokines, spray-dried plasma, interleukins or interferons, or a combination thereof.
[0128] Minerals that can be used in the present invention are, for example, boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, calcium, phosphorus, magnesium, potassium or sodium or a combination thereof.
[0129] Amino acids that can be used in the present invention are, for example, lysine, alanine, threonine, methionine or tryptophan or a combination thereof.
[0130] The composition of the invention may also contain betaine and / or choline and / or other physiologically effective methyl donors.The feed may also contain polyunsaturated fatty acids, in particular DHA and / or EPA.
[0131] Therefore, another embodiment of the present invention is also a method for preparing an animal feed composition, comprising mixing at least one microorganism and / or microbial preparation and / or feed additive of the present invention (especially in an amount effective to enhance animal health, especially intestinal health) with feed ingredients (such as proteins, lipids and / or carbohydrates) and optionally other beneficial substances (preferably as described above) to provide a feed product. The method may also include, for example, a pelleting step.
[0132] Standard pelleting methods known to those skilled in the art may be used, including extrusion processing of dry or semi-moist feeds.Preferred pelleting temperatures are between about 65°C and about 120°C.
[0133] The microorganisms, microbial preparations, feed additives and compositions of the present invention can be applied to animals in feed and / or drinking water and / or feeding water for many days during the entire life of the animal or in a specific stage or part of the animal's life. For example, the microorganisms and / or microbial preparations and / or compositions can be applied only in the basic feed of farm animals or only in fattening feed.
[0134] Microorganism, microbial preparation and composition of the present invention can also be used in a wide dosage range.Daily dosage is for example in the scope of about 1mg to about 500mg per kilogram of living body weight, particularly in the scope of about 5mg to about 200mg, in the scope of about 10mg to about 100mg, or in the scope of about 20mg to about 60mg.
[0135] According to the present invention, in embodiments of the present invention, preferably an effective amount of the microorganisms and / or microbial preparations and / or feed additives and / or compositions of the present invention is always used. The term "effective amount" refers to an amount that produces at least one beneficial effect on an animal and / or environment, in particular an amount of a beneficial effect with respect to the characteristics already mentioned above, compared to an animal or environment to which the microorganisms and / or microbial preparations and / or compositions of the present invention have not been administered, but to which the same diet (including feed and other compounds) or the same composition has been administered, respectively.
[0136] In the case of therapeutic applications, it is preferred to use a therapeutic amount of the microorganism and / or microbial preparation of the present invention and / or feed additive or food additive and / or composition. The term "therapeutic amount" refers to an amount sufficient to improve, reverse or prevent an animal disease state. Those skilled in the art can easily determine the optimal dosage level for a variety of animals by evaluating the ability of the composition, including (i) suppressing or reducing pathogenic viruses and / or bacteria in the gastrointestinal tract, particularly the intestinal tract, oral or nasopharyngeal cavity or skin or gills at various doses, (ii) increasing or maintaining the level of beneficial bacteria and / or (iii) enhancing animal health, particularly intestinal health, at various doses.
[0137] The method of the present invention can be used in all kinds of animals, in particular in all kinds of vertebrates, such as mammals, aquatic animals and birds.
[0138] Animals that may benefit from the present invention include, but are not limited to, farm animals, pets, exotic animals, zoo animals, animals used for sport, recreation, or work.
[0139] In a very preferred embodiment of the invention, the animals are farm animals, which are kept for consumption or as food producers, such as poultry, pigs and ruminants.
[0140] Poultry can be selected from productive poultry or domestic poultry, and also from ornamental poultry or wild birds. In this context, preferred productive poultry are chickens, turkeys, ducks and geese. In this context, productive poultry are preferably poultry optimized for producing young birds or poultry optimized for meat production. Preferred ornamental poultry or wild birds are peacocks, pheasants, partridges, partridges, guinea fowls, quails, ptarmigans, grouse, pigeons and swans, with quails being particularly preferred. Further preferred poultry are ratites, in particular ostriches and emus, and parrots.
[0141] The ruminants of the present invention are preferably selected from cattle, goats and sheep. In one embodiment, the composition of the present invention can be fed to pre-ruminants to enhance their health, in particular to reduce the incidence of diarrhea in these animals. Pre-ruminants are ruminants aged from birth to about twelve weeks, including calves.
[0142] The pet is preferably selected from the group consisting of dogs, cats, poultry and domesticated exotic animals. The animal used for sports may in particular be a horse.
[0143] The aquatic animals of the present invention are preferably finfish, in particular finfish or crustaceans of the class Actinopterygii. The class Actinopterygii includes in particular tilapia and other cichlids, carp and other cyprinids, salmon and other salmonids, catfish, in particular African catfish and pangasius, tuna, sea bass, cod, smelt, milkfish, mullet, sea bass, in particular barramundi, sea bream, grouper and snakehead fish.
[0144] In this context, preferred salmon and salmonids are Atlantic salmon, sockeye salmon (red salmon), mackerel (sakura salmon), Chinook salmon (Chinook salmon), trout (Chum salmon), coho salmon, Danube salmon, Pacific salmon, pink salmon and trout. The aquatic animal of the present invention is very preferably tilapia.
[0145] Crustaceans include shrimp, lobster, crab, prawns and crayfish, among others.
[0146] Preferred shrimp types in this context are of the genera Litopenaeus, Farfantepenaeus and Penaeus, in particular Penaeus stylirostris, Penaeus vannamei, Penaeus monodon, Penaeus chinensis, Penaeus occidentalis, Penaeus californiensis, Penaeus semisulcatus, Penaeus esculentu, Penaeus setiferus, Penaeus japonicus, Penaeus aztecus, Penaeus duorarum, Penaeus indicus, and Penaeus merguinis. merguiensis). Very preferred according to the invention is the whiteleg shrimp (Penaeus vannamei), also known as the whiteleg shrimp.
[0147] The aquatic animals (particularly shrimps) treated or fed with the microorganisms and / or preparations and / or compositions of the present invention may be juvenile shrimps, post-larvae shrimps or juvenile shrimps.
[0148] The aquatic animal may also be, in particular, fish, which are subsequently processed into fish meal or fish oil. In this respect, the fish is preferably herring, pollock, cod or small pelagic fish, such as anchovies, blue cod, capelin, pomfret, jack, mackerel, herring, sardine or trevally. The fish meal or fish oil thus obtained can in turn be used in aquaculture to cultivate food fish or crustaceans.
[0149] The aquatic animal may also be an oyster, a clam, a cockle, an ark shell, a bivalve, a mussel or a scallop.
[0150] However, aquatic animals may also be small organisms used as aquaculture feed. These small organisms may be in the form of nematodes, small crustaceans or rotifers, for example.
[0151] The farming of aquatic animals can be carried out in ponds, tanks, pools or isolated areas in the sea, lakes or rivers, in which case it is especially carried out in cages or net cages. Farming can be used to raise fish for fattening food, or to raise fry that are subsequently released to replenish wild fish stocks.
[0152] In salmon farming, the fish are preferably first grown to smolt in freshwater tanks or artificial raceways and then continue to grow in cages or nets floating in the sea, ponds or rivers and preferably moored in bays or fjords.
[0153] Therefore, the feed composition of the present invention is preferably a feed for feeding the above-mentioned animals. Preferred applications of the animal feed of the present invention are feeds for cattle, pigs, poultry, fish, crustaceans or companion animals, wherein pigs, in particular weaned piglets and poultry are particularly preferred. Spore-forming microorganisms, in particular spore-forming microorganisms of the genus Bacillus, are particularly suitable for this application because they produce heat-resistant spores, which can be mixed into the feed before the pelleting process of the animal feed. The microorganisms of the present invention are very preferably used in milk replacers for cattle, goats, sheep and pigs or as a post-granulation spray coating of granular feed materials.
[0154] The microorganisms and fermentation broth used in the present invention can be obtained by culturing the microorganisms of the present invention according to methods known in the art, including the use of culture media and other methods such as those described in Elisashvili et al. (Probiotics and Antimicrobial Proteins 11, 731-747 (2019)), Ren et al. (AMB Express 8: 21 (2018)) or as described in Report No. 179 of the Food and Agriculture Organization of the United Nations (FAO) entitled "Probiotics in Animal Nutrition" (Bajagai et al., FAO (2016)). Conventional large-scale microbial culture methods include submerged fermentation, solid-state fermentation, or liquid surface culture. Fermentation is to obtain high levels of colony-forming units of microbial cells. Optionally, the fermentation broth thus obtained can be washed, for example, by diafiltration, to remove residual fermentation broth and metabolites. The fermentation broth used to prepare the feed additive or food additive of the present invention preferably contains 5×10 10 cfu / g to 5×10 12 cfu / g of cells, more preferably containing 1×10 11 cfu / g to 4×10 12 cfu / g of cells.
[0155] Working Example
[0156] Example 1: Searching for conditions for effective absorption of external DNA
[0157] Bacillus velezensis strain CECT 5940 was used as the parent strain. The natural competence induction of this strain was monitored with the aid of a modified fluorescent reporter strain. The modified strain encodes a genomic copy of mNeonGreen (Shaner et al. (2013); Nat Methods 10(5):407–409) under the control of the promoter of the competent gene comGA. The reporter strain was obtained from the parent strain by amplifying the comGA promoter region using primers CACAATCACTGGCCGCAATG (SEQ ID NO:3) and TAGACTTCCCTCCTTCCGCAC (SEQ ID NO:4) using standard cloning techniques. Transcription of the homologous comGA gene was induced in competent Bacillus cells by the core competence activator protein comK. The reporter strain was used as a spore preparation, which was usually activated at 80°C for 10 minutes. To screen for conditions that could induce competence, the activated spores were placed in different media, using different dilution factors and incubation times. Incubations for germination (1 h, 25 °C) were performed in Eppendorf tubes in a Thermomix, while all subsequent incubation steps after germination were performed in 96-well deep-well plates (DWP) in a Duetz shaking system (Kühner AG, Switzerland). After a series of incubation steps, 100 μl of the sample was transferred from the DPW to the MTP and Fluorescence was detected in an Omega apparatus (BMG Labtech, Germany).
[0158] The results showed that the best fluorescence induction of strain CECT 5940 was obtained in cells that had been either a) germinated in 100 μl HS supplemented with AGFK followed by a 2-hour incubation with the addition of 500 μl MG12 or b) germinated in 200 μl HS supplemented with AGFK followed by a 3-hour incubation with the addition of 1000 μl mF12. Longer and shorter incubation steps resulted in a much lower overall fluorescence and a lack of visible fluorescent cells under microscopic observation. Conversely, conditions in which the overall fluorescence was significantly increased also resulted in the detection of fluorescent cells under the microscope.
[0159] Example 2: Generation of safe strains
[0160] The chromosomal comK locus was selected to generate the restricted strain because it is a core competent regulator (van Sinderen et al. (1995); Mol Microbiol. 15 (3): 455-62). The mutagenesis target was placed in the comK open reading frame. Two stop codons were introduced into comK by two point mutations at positions 10 and 37, and another point mutation was introduced at position 35 to generate a new HindIII restriction enzyme site, which was used to detect successful mutants by colony PCR digestion. This was achieved by using a single PCR product from PCR, which used primer pairs com1 / com2 and com3 / com4 as templates for overlap extension PCR to generate the final mutagenesis cassette. The mutation was introduced by primers com2 and com3, which also had a common overlap region, suitable for generating the final mutagenesis cassette in overlap extension PCR using primer pairs com1 / com4.
[0161]
[0162] To select for successful introduction of the DNA, the chromosomal pyrE (encoding orotate phosphoribosyltransferase) locus was chosen as a selectable marker. This gene can be used for bidirectional selection (Sakaguchi et al. (2013); Biosci Microbiota Food Health. 32(2):59–68). Cells with inactivated pyrE become uracil auxotrophs and can be selected by their resistance to 5-fluoroorotic acid (5-FOA). The mutagenesis cassette for pyrE inactivation was designed to introduce two stop codons into the open reading frame of pyrE by two SNPs. This was achieved by using a single PCR product from PCR using primer pairs pyr1 / pyr2 and pyr3 / pyr4 as templates for overlap extension PCR to generate a final mutagenesis cassette of 1825 bp. The mutation was introduced by primers pyr2 and pyr3, which also share an overlapping region suitable for generating the final mutagenesis cassette in overlap extension PCR using primer pair pyr1 / pyr4.
[0163] pyr1 TCCGGATGGTATACGAAGTCAG (SEQ ID NO: 9)
[0164] pyr2 TCAATGTGTAATAGATGTTATGCGATAGCC (SEQ ID NO: 10)
[0165] pyr3 TCTATTACACATTGAAGCTGTCTTTTAACGCCCGAATGAG (SEQ ID NO: 11)
[0166] pyr4 TCCAGCGGAATGAAAGACAGTG (SEQ ID NO: 12)
[0167] Subsequently, in order to identify variants with pyrE inactivation, a series of concentrations of 5-FOA were tested by plating the parent strain CECT 5940 on minimal medium (MM, see Appendix for culture medium) agar plates. MM plates supplemented with the solvent DMSO (for 5-FO mother solution) were used as growth controls. The parent strain CECT 5940 had been completely inhibited by supplementing 10 mg / L 5-FOA on MM plates. When the agar medium was supplemented with 10 μg / ml uracil, the inhibition of the parent strain by 5-FOA still occurred with the same effectiveness. Subsequently, agar plates containing 10 mg / ml 5-FOA and 10 μg / ml uracil concentrations were successfully used to screen pyrE inactivated mutants. The genotype of the resulting pyrE inactivated (uracil auxotrophic) mutant strain was confirmed by sequencing the PCR products covering the mutagenesis site.
[0168] The pyrE inactivated strain thus obtained was used as recipient cell for co-transformation using a mutagenic cassette for comK inactivation together with a pyrE wild-type cassette followed by selection for prototrophy. Both mutagenic cassettes were generated by fusion of two separate PCR products by overlap extension PCR. The mutagenic site was located in the center with 450 bp-500 bp of unmutated sequence as homologous recombination flanks. The wild-type pyrE cassette used in the co-transformation with the comK mutagenic cassette was generated in a single PCR using only the outer primers pyr1 / pyr4.
[0169] Transformants that can grow on minimal medium (MM) agar plates were re-streaked onto MM agar to verify their prototrophic state, and then the presence of the desired mutation comK was checked by PCR product sequencing. Three verified clones were subsequently selected for genome sequencing (Illumina, gDNA prepared using MasterPure Grampositive gDNA Kit). The results of the resequencing were bioinformatically compared with the wild-type genome sequence and the presence of point mutations was checked. All three clones showed the desired mutation in the comK locus, two of which had no other mutations at the non-target locus. The third clone still carried the mutation in pyrE from the original strain. Based on these results, two clones without non-target mutations were selected for phenotypic analysis.
[0170] Example 3: Evaluation of the phenotype of comK knockout mutants
[0171] The competence phenotype of two verified comK mutant strains was evaluated by testing the transformation efficiency of plasmid DNA of natural competence. Two independent cultures of each strain were used for transformation, and the parent strain CECT 5940 was used as a negative control. Each transformation reaction included 25 μg of a plasmid DNA mother solution (a shuttle vector carrying Tet resistance), which had been separated from the CECT 5940 transformant to maximize the transformation efficiency. The transformation efficiency of the parent strain reached 0.5-1 / μgDNA, while the comK inactivated mutant did not produce any transformants. This confirms that the ability of the mutant to absorb DNA through natural competence is completely lost as expected. In addition to the lack of the ability to absorb DNA through natural competence, the mutant thus obtained also has all the characteristics of the parent strain CECT 5940. Therefore, the introduction of the mutation eliminates the risk that the strain may acquire undesirable antibiotic resistance genes after being released into the environment, but on the other hand, the introduction of the mutation has no adverse effect on the probiotic activity of the strain.
Claims
1. Microorganisms with reduced competence.
2. A microorganism according to claim 1, wherein the microorganism has probiotic activity, in particular the ability to inhibit pathogenic bacteria, the ability to grow in the presence of bile and / or the ability to produce organic acids, preferably lactic acid, wherein the pathogenic bacteria are preferably selected from Clostridium perfringens, Salmonella enteritidis, Salmonella typhimurium, Escherichia coli, Clostridium difficile, Vibrio parahaemolyticus and combinations thereof.
3. A microorganism according to claim 1 or 2, wherein the competence of the microorganism is reduced by at least 20%, more preferably at least 50%, 70% or 90%, and wherein the microorganism is preferably not able to take up DNA at all by natural transformation.
4. The microorganism according to any one of the preceding claims, wherein the microorganism contains at least one competent gene with reduced activity, preferably at least one competent gene that is knocked out, wherein the competent gene is preferably a transcription factor.
5. A microorganism according to claim 4, wherein the competent gene with reduced activity, preferably the competent gene that is knocked out, is comK, which encodes the competent transcription factor ComK, and wherein the comK mutant gene preferably shows 1 to 20 mutations, more preferably 1 to 10 mutations, most preferably 1 to 5 mutations compared to the functionally expressed comK gene, and wherein preferably at least one of the mutations results in the introduction of a stop codon in the comK sequence.
6. The microorganism according to any one of the preceding claims, wherein the microorganism belongs to the phylum Bacillota, preferably to the genus Bacillus, more preferably to B. subtilis, B. amyloliquefaciens, B. velezensis, B. licheniformis, B. paralicheniformis, B. pumilus, B. megaterium, B. lentus, B. laterosporus, B. alevi, B. cereus, B. badius, B. thurigiensis, B. coagulans lans, B. siamensis, B. glycinifermentans, B. methylotrophicus, B. thuringiensis, B. polyfermenticus, B. vallismortis, B. tequilensis, B. atrophaeus, B. mojavensis, B. sonorensis, B. inaquosus and B. safensis, in particular species belonging to Bacillus subtilis, Bacillus velez, Bacillus amyloliquefaciens, Bacillus brevis or Bacillus megaterium, in particular species belonging to Bacillus amyloliquefaciens or Bacillus velez.
7. A microorganism according to any of the preceding claims, wherein the strain is a Bacillus Velez strain and the genomic DNA of the strain is preferably at least 99%, preferably at least 99.5% or 99.9%, most preferably at least 99.99% identical to the genomic DNA of strain CECT 5940.
8. A method for obtaining a microorganism with reduced competence according to any one of claims 1 to 7, comprising the following steps: a) introducing a reporter gene downstream of the promoter of the gene activated by the competent gene, wherein the reporter gene preferably encodes a fluorescent marker, so that activation of the promoter leads to expression of the reporter gene; b) screening conditions leading to competence induction by analyzing the microorganisms in terms of the expression level of the reporter gene; c) introducing a knockout into the gene of the microorganism, which results in auxotrophy of the strain and resistance of the strain thus transformed to a specific substance; d) searching for the knockout strain obtained in step (c) by screening strains with desired resistance; e) co-transforming the strain identified in step (d) with an active form of the gene knocked out in step (c) and a knockout variant of the competent gene, f) searching for strains that exhibit prototrophy; g) Screening the strain identified in step (f) to determine whether knockout of the competent gene is successful.
9. The method of claim 8, wherein the competent gene is comK, the knockout gene introduced in step (c) is a knockout variant of pyrE, and the strain becomes auxotrophic for uracil and resistant to 5-FOA, and the co-transformation in step (e) is performed using an active form of pyrE and a knockout variant of comK.
10. The method according to claim 8 or 9, wherein the microorganism is of the phylum Bacillus, preferably of the genus Bacillus, more preferably of a species of Bacillus subtilis, Bacillus velez, Bacillus amyloliquefaciens, Bacillus brevis or Bacillus megaterium, especially a species of Bacillus amyloliquefaciens or Bacillus velez.
11. A feed additive or food additive comprising a microorganism according to any one of claims 1 to 7.
12. A feed or food composition comprising a microorganism according to any one of claims 1 to 7 or a feed or food additive according to claim 11 and preferably at least one other feed or food ingredient selected from carriers, proteins, carbohydrates, fats, other probiotics, prebiotics, enzymes, vitamins, immunomodulators, milk replacers, minerals, amino acids, carriers, coccidiostats, acid-based products and / or drugs, such as antibiotics.
13. A pharmaceutical composition comprising the microorganism according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
14. Use of a microorganism according to any one of claims 1 to 7 and / or a feed additive or food additive according to claim 11 and / or a feed composition or food composition according to claim 12 for the preparation of a composition for enhancing animal health and / or improving the general physical condition of an animal and / or improving the feed conversion rate of an animal and / or reducing the mortality rate of an animal and / or increasing the survival rate of an animal and / or improving the weight gain of an animal and / or increasing the productivity of an animal and / or enhancing the disease resistance of an animal and / or modulating the immune response of an animal and / or establishing or maintaining a healthy intestinal microbiota of an animal and / or improving the meat quality of an animal and / or reducing the transmission of bacterial and / or viral pathogens through animal feces.
15. A method for raising animals, wherein the animals are raised with the microorganism according to any one of claims 1 to 7 and / or the feed additive according to claim 11 and / or the feed composition according to claim 12.
Citation Information
Patent Citations
Feeds
US4919936A
Inhibition of pathogens by probiotic bacteria
US6849256B1
Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US7247299B2
Peniophora phytase
WO1998028408A1
Improved phytases
WO2000043503A1
